Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics

Wall Street analysts forecast that Insmed (INSM) will report quarterly loss of $1.15 per share in its upcoming release, pointing to a year-over-year increase of 10.2%. It is anticipated that revenues will amount to $103.02 million, exhibiting an increase of 23.1% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 6.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.With that in mind, let's delve into the average projections of some Insmed metrics that are commonly tracked and projected by analysts on Wall Street.The combined assessment of analysts suggests that 'Revenue- Japan' will likely reach $30.72 million. The estimate indicates a change of +46.6% from the prior-year quarter.Based on the collective assessment of analysts, 'Revenue- Europe and rest of world' should arrive at $5.93 million. The estimate indicates a change of +32.3% from the prior-year quarter.It is projected by analysts that the 'Revenue- U.S.' will reach $67.81 million. The estimate indicates a change of +16.4% from the prior-year quarter.View all Key Company Metrics for Insmed here>>>Insmed shares have witnessed a change of +9.4% in the past month, in contrast to the Zacks S&P 500 composite's +4.7% move. With a Zacks Rank #3 (Hold), INSM is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Insmed, Inc. (INSM): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks